You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
According to a US Food and Drug Administration webinar yesterday, a lot of IDT test kits has been qualified by CDC and is authorized for purchase.
Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.
The device is designed to stabilize RNA and DNA from fingerstick blood at room temperature for up to two weeks so that it can be mailed to a lab for analysis.
Thermo Fisher will pay €39 ($43.35) per share of Qiagen's stock, a premium of about 23 percent on the stock's closing price on the Frankfurt Prime Standard on March 2.
More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.
The funding, part of a larger initiative by Genome Canada, will support two studies in British Columbia that will evaluate genomics in healthcare.
Patients with luminal breast cancer subtypes may do just as well without anthracycline-based chemo and avoid unnecessary toxicities, a study showed.
Of the 32 firms included in the GW Index, 27 saw their stock prices drop while only five saw gains. Yet, the GW Index outperformed the Dow and Nasdaq.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
The product uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells.
Pursuant to expanded guidelines announced over the weekend, New York State public health labs have been granted emergency authorization.
The firm has entered into a securities purchase agreement for the issuance and sale of 23 million shares of its common stock at $0.40 per share.
Researchers will use the VCurePrecision EMR platform to improve understanding of cancer, and doctors can use it make care decisions for patients.
The qualitative in vitro nucleic acid amplification assay detects 2019-mCoV using RT-PCR from throat swab and bronchoalveolar lavage fluid samples.
The deal gives DiaSorin the exclusive rights to TTP's sample-to-answer diagnostic system for human in vitro diagnostic applications.
Multi-omics approaches can give insight into the gut microbiome and more, but there are still challenges to address, speakers at the ABRF meeting said.
The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.
La Jolla, California-based DermTech has agreed to sell common and preferred stock to a number of undisclosed institutional investors.
The three-year contract secures standardized pricing for HPG-affiliated facilities across the US and offers access to NeoGenomics' testing services.
The government payor is interested in public input on the evidence underlying the blood-based PCR test.
The agency issued guidance, effective immediately, that describe the circumstances in which it will allow labs to perform such testing.
The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.
Labs can deploy the test kit omitting the pan-SARS component, and new kits that are specific only to SARS-CoV-2 are being manufactured.
The partners will use Medidata's machine learning-based biomarker discovery platform to investigate the amyotrophic lateral sclerosis disease process.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.